Pharnext raises €2.5 million for Pleodrug progress
This article was originally published in Scrip
Executive Summary
French biotechnology company Pharnext has raised €2.5 million (corresponding to a pre-money company valuation of €60 million), in what the company hopes will be a €10 million financing round expected to close at the end of the year.